Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Yim, Sun Young | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Lee, Yu Rim | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Kim, Hong Soo | - |
dc.contributor.author | Kim, Byung Ik | - |
dc.contributor.author | Um, Soon Ho | - |
dc.date.available | 2020-11-02T07:04:18Z | - |
dc.date.issued | 2018-08 | - |
dc.identifier.issn | 0002-9270 | - |
dc.identifier.issn | 1572-0241 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/3313 | - |
dc.description.abstract | OBJECTIVES: For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen. This study aims to investigate whether ciprofloxacin once weekly administration is not inferior to norfloxacin once daily administration for the prevention of SBP. METHODS: This is an investigator-initiated open-label randomized controlled trial conducted at seven tertiary hospitals in South Korea. Liver cirrhosis patients with ascites were screened, and enrolled in this randomized controlled trial if ascitic protein <= 1.5 g/dL or the presence of history of SBP. Ascitic polymorphonucleated cell count needed to be <250/mm(3). Patients were randomly assigned into norfloxacin daily or ciprofloxacin weekly group, and followed-up for 12 months. Primary endpoint was the prevention of SBP. RESULTS: One hundred twenty-four patients met enrollment criteria and were assigned into each group by 1: 1 ratio (62: 62). Seven patients in the norfloxacin group and five patients in the ciprofloxacin group were lost to follow-up. SBP developed in four patients (4/55) and in three patients (3/57) in each group, respectively (7.3% vs. 5.3%, P = 0.712). The transplant-free survival rates at 1 year were comparable between the groups (72.7% vs. 73.7%, P = 0.970). Incidence of infectious complication, hepatorenal syndrome, hepatic encephalopathy, and variceal bleeding rates were not significantly different (all P = ns). The factors related to survival were models representing underlying liver function. CONCLUSION: Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.title | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1038/s41395-018-0168-7 | - |
dc.identifier.scopusid | 2-s2.0-85049115598 | - |
dc.identifier.wosid | 000442492800013 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF GASTROENTEROLOGY, v.113, no.8, pp 1167 - 1176 | - |
dc.citation.title | AMERICAN JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 113 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1167 | - |
dc.citation.endPage | 1176 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | MULTIDRUG-RESISTANT BACTERIA | - |
dc.subject.keywordPlus | PRIMARY PROPHYLAXIS | - |
dc.subject.keywordPlus | PORTAL-HYPERTENSION | - |
dc.subject.keywordPlus | CIRRHOTIC-PATIENTS | - |
dc.subject.keywordPlus | ESCHERICHIA-COLI | - |
dc.subject.keywordPlus | LIVER-CIRRHOSIS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ASCITES | - |
dc.subject.keywordPlus | RIFAXIMIN | - |
dc.subject.keywordPlus | INFECTIONS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.